Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor Fitzgerald
September 26, 2018 9:33 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.
Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More
Aldeyra Therapeutics (ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial
September 26, 2018 7:33 AM EDTAldeyra Therapeutics (NASDAQ: ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial
... More